[
  {
    "ts": null,
    "headline": "Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
    "summary": "Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger. The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with ... Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
    "url": "https://finnhub.io/api/news?id=1efa10e9cb234652eae54435b33fde1e0b6452547cd96ec10b441a225413b784",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768496156,
      "headline": "Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
      "id": 138126438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger. The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with ... Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
      "url": "https://finnhub.io/api/news?id=1efa10e9cb234652eae54435b33fde1e0b6452547cd96ec10b441a225413b784"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
    "url": "https://finnhub.io/api/news?id=bbfd391d9f8f10e71e49dace0086a3bd81f1b55ce02d42df5ea273c7dd6618c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768479722,
      "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
      "id": 138120717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
      "url": "https://finnhub.io/api/news?id=bbfd391d9f8f10e71e49dace0086a3bd81f1b55ce02d42df5ea273c7dd6618c5"
    }
  }
]